Here we outline our two methods for issuing grants, Request for Grant Proposals and Current Grant Offers.

REQUEST FOR GRANT PROPOSALS – is committed to raising funds for research directed towards discovering pathophysiology, trialing treatments, and finding a cure for New Daily Persistent Headache.  We are looking for projects that will help advance understanding and treatment for chronic unremitting unresponsive headaches.

We welcome all proposals relevant to basic or clinical chronic headache research.  We are particularly interested in innovative, multidisciplinary approaches encompassing, nervous system, venous system, immune system, neuro-inflammation, genetics, mitochondrial dysfunction, and homeostasis dysregulation.

If you are interested in proposing a study and applying for a grant, complete the application below. If you have questions, email us at


All grants must be used exclusively for research. Capital expenditures, administrative costs, institutional overhead including IRB approval, publication costs, and travel costs will not be funded. Salaries are capped at 25% of the grant.

Grant Application Format

Please use the following application format:

  1. Project Title:
  2. Principal Investigator contact information: name, mailing address, phone number, and email address for each PI.
  3. Institutional Grants Administration Officer contact information: name, mailing address, phone number and email address.
  4. Location(s):
  5. Abstract: Provide a succinct lay summary of the project rationale or hypothesis. Include why it is innovative, should be considered for funding, and how it may lead to a better understanding of headache or the treatment of headache patients.
  6. Duration: Explain how long you think it will take to complete this project.
  7. Recruitment: For clinical projects, briefly explain your plan for recruiting participants and estimated number of participants.
  8. Has work already begun on this line of inquiry in your lab? If yes, explain.
  9. Does this research duplicate other research, either in your lab or elsewhere? If yes, explain.
  10. Do you have any pending applications for research funding that include this project? If yes, explain.
  11. PROPOSAL:. Describe your overall research plan. Please reference any other studies that influence the basis of the proposed study.
  12. BUDGET: Attach a Budget with grant request.  All grants must be used exclusively for research. Capital expenditures, administrative costs, institutional overhead including IRB approval, publication costs and travel costs will not be funded. Salaries are capped at 25% of grant. NIH study format with IRB.
  13. Attach an NIH Bio-sketch for the Principal Investigator(s).

Email your application to:

Current Grant Offers – 

New Daily Persistent Headache being under-researched and poorly understood, we hope to bring interest and possibly demonstrate involved pathways of mechanism for future study.   We believe that some NDPH patients have more in common with chronic migraine, fibromyalgia, POTS, Hypermobility, EDS, PTSD, ME/CFS, than with episodic migraineurs.  66% of chronic migraineurs also present with fibromyalgia.  We find subsets of NDPH patients have comorbidities such as POTS, Hypermobility, Fibromyalgia, and Ehlers-Danlos syndrome.  We are open to the idea that NDPH is not a subset of migraine at all and that perhaps it should be studied along with complex neuroinflammatory conditions driven by some metabolic dysfunction.

Here we present the studies we would like to see trialed in the clinic setting.   All studies are to be open-label uncontrolled. A minimum of 10 study patients per trial. The trial may consist of one or more offices directed by the principal investigator.  These suggested trials are not designed, recommended or administered by our Medical Advisory Board.

The patient body is to be defined per section 4.10 of ICHD-3: No suspected cervicogenic or other primary diseases with headache presenting as secondary.  Each grant offer outlines a basic treatment trial.  The actual treatment protocol, including ethics, NIH guidelines, IRB compliance, budget management etc are to be devised and implemented by the principal investigator.

Please contact us if you are interested in conducting any of the following.

Nebulized Glutathione

Cohort: 10 patients minimum, post upper respiratory onset.

Medications/Therapies: Inhaled (Nebulized or Aerosolized) Glutathione

Dosage: 600mg twice daily

Duration: 14 days

Premise: Post-upper respiratory onset of NDPH is poorly understood.  There is some speculation of an activated immune response triggering an immune molecule stuck in a loop by under-production of organ specific glutathione and excess oxidative stress.  There is research supporting inhaled glutathione passing the blood brain barrier and as a therapy for Cystic Fibrosis, Chronic Rhinitis, Chronic Ear Fullness and Multiple Chemical Sensitivity.  Some post upper respiratory onset NDPH patients report ear fullness and multiple chemical sensitivity.

If you are interested in a grant for any of the above suggested trials, send us an email at